Vacancies
HER-care is committed to attract talented, motivated researchers from around the world to join our innovative network on breast cancer research. We offer doctoral positions within a vibrant, international environment that combines cutting-edge science, state-of-the-art training, and strong connections to industry.
Marie Skłodowska-Curie Actions Doctoral Network (MSCA-DN) programs are prestigious European Commission-funded initiatives designed to train the next generation of researchers. They offer high-quality doctoral education, international mobility, and strong links between academia, industry and society.
Why join HER-CARE?
- World-class training – benefit from a unique program of scientific, technical and transferable skills training
- International collaboration – work alongside leading academic and industrial partners from across the world
- Career development – gain experience in multidisciplinary research, peer mentoring, and event organisation
- Impactful research – contribute to developing personalized prevention and clinical management strategies for breast cancer.
Eligibility requirements for MSCA-DN Doctoral Candidates
- You must not already hold a doctoral degree at the time of recruitment. Researchers who have successfully defended their PhD (even if not formally awarded yet) are not eligible.
- You must not have resided or carried out your main activity (work, studies, etc.) in the host country for more than 12 months in the 36 months immediately before your recruitment date. Short stays such as holidays are not counted.
- You must be able to start the position on the agreed date and commit to a full-time employment for the duration of your appointment.
- Good proficiency in English (spoken and written) is required, as it is the working language of the project.
Current opportunities
|
Doctoral Candidate project (no.) |
Required expertise |
Desirable |
Host institution |
Location |
Application deadline |
|
DC1 | Improving classification of pathogenetic variants |
Epidemiology, bioinformatics, statistics |
AI, genetics |
CING |
Nicosia, Cyprus |
|
|
DC2 | Identifying novel regulatory variants |
Bioinformatics, AI, statistics |
Epidemiology, genetics |
CCGE |
Cambridge, UK |
|
|
DC3 | Developing multi-ancestry risk prediction models |
Statistics, epidemiology, data science |
Genetics |
ICR |
Cambridge, UK |
|
|
DC4 | Understanding the impact of hormone replacement therapy (HRT) in BRCA1/2 carriers |
Epidemiology, genetics, biomedical sciences |
Clinical research, statistics |
MUW |
Vienna, Austria |
|
|
DC5 | Novel risk prediction tools for early onset of 1st and/or 2nd breast cancer |
Epidemiology, statistics |
Bioinformatics, clinical research, biomedical sciences |
NKI |
Amsterdam, the Netherlands |
December 31, 2025 |
|
DC6 | Novel risk factors/markers for early onset cancer and prediction models, including hereditary breast cancer |
Biomedical sciences |
Bioinformatics, AI, epidemiology |
UU |
Utrecht, the Netherlands |
|
|
DC7 | Novel risk factors/markers for early onset cancer and prediction models, including hereditary breast cancer |
Bioinformatics, AI, molecular biology |
Statistics |
OUH |
Odense, Denmark |
|
|
DC8 | Field-ready minimally invasive assay for early-stage organismal adaptations |
Data science |
Bioinformatics, AI, biomedical sciences |
GR |
Villejuif, France |
|
|
DC9 | (Non)-mammographic markers to identify high/low breast cancer risk |
Bioinformatics, AI, epidemiology, public health |
Statistics, biomedical imaging |
KI |
Stockholm, Sweden |
|
|
DC10 | Novel risk prediction tools for early onset of 1st and/or 2nd breast cancer |
Statistics, epidemiology |
Bioinformatics, AI, genetics |
NKI |
Amsterdam, the Netherlands |
December 31, 2025 |
|
DC11 | Digital infrastructure for interoperable clinical communications |
Bioinformatics, AI, biomedical sciences |
Clinical research, data science |
EVI |
Haaksbergen, the Netherlands |
December 31, 2025 |
|
DC12 | Novel molecular or germline biomarkers to inform diagnosis/prognosis |
Bioinformatics, AI, statistics |
Epidemiology, genetics |
NKI |
Amsterdam, the Netherlands |
|
|
DC13 | Novel molecular or germline biomarkers to inform diagnosis/prognosis |
Bioinformatics, AI |
Clinical research, genetics |
CNAG |
Barcelona, Spain |
|
|
DC14 | ML/AI models linking protein cross-section signatures to immune/proteomic changes |
Bioinformatics, AI |
Epidemiology, biomedical sciences, data science |
PRO |
London, UK |
|
|
DC15 | Novel multi-modal models for breast cancer treatment prediction |
Bioinformatics, AI, biomedical sciences |
Molecular biology, genetics, data science |
MUW |
Vienna, Austria |
|
How to apply
Please follow the application instructions provided in each vacancy announcement. Unless otherwise stated, application should include:
- A motivation letter
- A detailed CV (including publications, if any)
- Contact details of at least two referees
For questions about the recruitment process, contact the HER-CARE Project Manager.